Leerink Partners Maintains Market Perform on Arrowhead Pharma, Raises Price Target to $72
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perform and raises the price target from $61 to $72.
Leerink Partners analyst Mani Foroohar maintains Arrowhead Pharma (NASDAQ:ARWR) with a Market Perform and raises the price target from $61 to $72.